New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2025, WHO consolidated guidelines on tuberculosis: module 4: treatment and care
View latest version (2025)Bibliographic Info
GuidelineWHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment
Year of Publication2020
Issuing InstitutionWorld Health Organization
Recommendation
Status
Retired
Recommended in favor
Conditional
Certainty of evidence
Very low
A treatment regimen lasting 6–9 months, composed of bedaquiline, pretomanid and linezolid (BPaL), may be used under operational research conditions in multidrug-resistant tuberculosis (MDR-TB) patients with TB that is resistant to fluoroquinolones, who have either had no previous exposure to bedaquiline and linezolid or have been exposed for no more than 2 weeks.